SG11202001786PA - Il-33 antagonist-containing therapeutic agent for endometriosis - Google Patents
Il-33 antagonist-containing therapeutic agent for endometriosisInfo
- Publication number
- SG11202001786PA SG11202001786PA SG11202001786PA SG11202001786PA SG11202001786PA SG 11202001786P A SG11202001786P A SG 11202001786PA SG 11202001786P A SG11202001786P A SG 11202001786PA SG 11202001786P A SG11202001786P A SG 11202001786PA SG 11202001786P A SG11202001786P A SG 11202001786PA
- Authority
- SG
- Singapore
- Prior art keywords
- endometriosis
- antagonist
- therapeutic agent
- containing therapeutic
- agent
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552594P | 2017-08-31 | 2017-08-31 | |
| PCT/JP2018/032494 WO2019045075A1 (en) | 2017-08-31 | 2018-08-31 | Il-33 antagonist-containing therapeutic agent for endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001786PA true SG11202001786PA (en) | 2020-03-30 |
Family
ID=65525625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001786PA SG11202001786PA (en) | 2017-08-31 | 2018-08-31 | Il-33 antagonist-containing therapeutic agent for endometriosis |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11492398B2 (en) |
| EP (1) | EP3677281A4 (en) |
| JP (3) | JP7177446B2 (en) |
| KR (1) | KR20200044812A (en) |
| CN (4) | CN115920032A (en) |
| AU (1) | AU2018325645A1 (en) |
| BR (1) | BR112020003458A2 (en) |
| CA (1) | CA3074421A1 (en) |
| IL (1) | IL272864B2 (en) |
| MX (1) | MX2020002086A (en) |
| PH (1) | PH12020500400A1 (en) |
| SG (1) | SG11202001786PA (en) |
| TW (2) | TW202306586A (en) |
| WO (1) | WO2019045075A1 (en) |
| ZA (1) | ZA202001256B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4223874A3 (en) | 2013-12-26 | 2023-09-27 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| WO2020054871A1 (en) * | 2018-09-14 | 2020-03-19 | 田辺三菱製薬株式会社 | Human anti-il-33 monoclonal-antibody-containing pharmaceutical composition |
| WO2023157895A1 (en) * | 2022-02-17 | 2023-08-24 | 国立大学法人 鳥取大学 | Prophylactic agent or therapeutic agent for endometriosis or adenomyosis |
| CN114712509A (en) * | 2022-04-01 | 2022-07-08 | 首都医科大学附属北京妇产医院 | Novel use of IL-33 antagonists |
| WO2024005634A1 (en) * | 2022-06-28 | 2024-01-04 | Stichting Vumc | Anti-angiogenic therapy as treatment for benign uterine disorders |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ES2134212T3 (en) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN. |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
| KR101222450B1 (en) | 1999-03-25 | 2013-01-16 | 애보트 게엠베하 운트 콤파니 카게 | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US7615619B2 (en) | 2002-02-13 | 2009-11-10 | Takeshi Imanishi | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| ES2382807T3 (en) | 2003-08-28 | 2012-06-13 | Takeshi Imanishi | New artificial nucleic acids of the N-O link type with cross-linking |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2006055638A2 (en) | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| NZ563213A (en) | 2005-06-01 | 2009-07-31 | Micromet Ag | Anti-IL2 antibodies |
| PT2314623E (en) | 2005-06-21 | 2012-10-02 | Xoma Technology Ltd | Il-1beta binding antibodies and fragments thereof |
| WO2008074004A2 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| CA2685124A1 (en) | 2007-04-26 | 2008-11-06 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin | Products for altering il-33 activity and methods therefor |
| US20100260770A1 (en) | 2007-05-18 | 2010-10-14 | Medimmune, Llc | Il-33 in inflammatory disease |
| WO2010000721A1 (en) | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| JP2012502967A (en) | 2008-09-19 | 2012-02-02 | メディミューン，エルエルシー | Antibodies against sonic hedgehog homologs and uses thereof |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| CN102596983B (en) | 2009-10-29 | 2016-06-15 | 国立大学法人大阪大学 | The artificial nucleosides of cross-linking type and nucleotides |
| FR2972006B1 (en) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | NOVEL IL-33 SUPERACTIVE FRAGMENTS AND USES THEREOF |
| CN104768964B (en) | 2012-09-21 | 2017-03-29 | 国立大学法人大阪大学 | Artificial nucleoside with guanidine bridge and oligonucleotide |
| JO3532B1 (en) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
| EA034834B1 (en) | 2013-03-15 | 2020-03-26 | Ридженерон Фармасьютикалз, Инк. | Il-33 antagonists and uses thereof |
| EP4223874A3 (en) | 2013-12-26 | 2023-09-27 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| RU2019118984A (en) | 2014-01-10 | 2019-08-06 | Анаптисбайо, Инк. | ANTIBODIES AIMED AGAINST INTERLEUKIN-33 (IL-33) |
| WO2016031932A1 (en) | 2014-08-27 | 2016-03-03 | 田辺三菱製薬株式会社 | METHOD FOR PRODUCING PROTEIN HAVING Fc REGION BY ALKALI WASHING |
| JP7231326B2 (en) * | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| US10500273B2 (en) | 2015-03-02 | 2019-12-10 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
| EP3277717B1 (en) | 2015-03-31 | 2020-11-18 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| JP6501650B2 (en) | 2015-06-25 | 2019-04-17 | 田辺三菱製薬株式会社 | Human anti-IL-33 neutralizing monoclonal antibody |
| CN108137682A (en) * | 2015-10-06 | 2018-06-08 | 瑞泽恩制药公司 | Biomarker related with the disease of interleukin-33 (IL-33) mediation and application thereof |
| CA3054386A1 (en) | 2017-03-01 | 2018-09-07 | Medimmune Limited | Formulations of monoclonal antibodies |
| WO2020054871A1 (en) | 2018-09-14 | 2020-03-19 | 田辺三菱製薬株式会社 | Human anti-il-33 monoclonal-antibody-containing pharmaceutical composition |
-
2018
- 2018-08-31 IL IL272864A patent/IL272864B2/en unknown
- 2018-08-31 EP EP18851250.3A patent/EP3677281A4/en active Pending
- 2018-08-31 CN CN202210827811.3A patent/CN115920032A/en active Pending
- 2018-08-31 US US16/643,502 patent/US11492398B2/en active Active
- 2018-08-31 TW TW111135982A patent/TW202306586A/en unknown
- 2018-08-31 WO PCT/JP2018/032494 patent/WO2019045075A1/en active Application Filing
- 2018-08-31 TW TW107130594A patent/TWI825025B/en active
- 2018-08-31 CN CN202210826001.6A patent/CN115920031A/en active Pending
- 2018-08-31 SG SG11202001786PA patent/SG11202001786PA/en unknown
- 2018-08-31 KR KR1020207005066A patent/KR20200044812A/en active IP Right Grant
- 2018-08-31 CN CN201880056633.0A patent/CN111107875A/en active Pending
- 2018-08-31 MX MX2020002086A patent/MX2020002086A/en unknown
- 2018-08-31 CA CA3074421A patent/CA3074421A1/en active Pending
- 2018-08-31 JP JP2019539686A patent/JP7177446B2/en active Active
- 2018-08-31 AU AU2018325645A patent/AU2018325645A1/en active Pending
- 2018-08-31 BR BR112020003458-4A patent/BR112020003458A2/en unknown
- 2018-08-31 CN CN202210826367.3A patent/CN115920041A/en active Pending
-
2020
- 2020-02-27 ZA ZA2020/01256A patent/ZA202001256B/en unknown
- 2020-02-28 PH PH12020500400A patent/PH12020500400A1/en unknown
-
2022
- 2022-07-15 US US17/813,016 patent/US20220372130A1/en active Pending
- 2022-11-02 JP JP2022176101A patent/JP7441473B2/en active Active
-
2024
- 2024-02-08 JP JP2024018036A patent/JP2024045481A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI825025B (en) | 2023-12-11 |
| IL272864A (en) | 2020-04-30 |
| CN115920041A (en) | 2023-04-07 |
| TW201919706A (en) | 2019-06-01 |
| IL272864B1 (en) | 2023-11-01 |
| AU2018325645A1 (en) | 2020-02-27 |
| US11492398B2 (en) | 2022-11-08 |
| JPWO2019045075A1 (en) | 2020-08-20 |
| CN115920032A (en) | 2023-04-07 |
| JP7177446B2 (en) | 2022-11-24 |
| JP2024045481A (en) | 2024-04-02 |
| JP2022190064A (en) | 2022-12-22 |
| RU2020108574A3 (en) | 2021-09-16 |
| EP3677281A4 (en) | 2021-05-12 |
| EP3677281A1 (en) | 2020-07-08 |
| US20200190182A1 (en) | 2020-06-18 |
| RU2020108574A (en) | 2021-08-30 |
| ZA202001256B (en) | 2023-10-25 |
| CA3074421A1 (en) | 2019-02-07 |
| US20220372130A1 (en) | 2022-11-24 |
| CN115920031A (en) | 2023-04-07 |
| IL272864B2 (en) | 2024-03-01 |
| TW202306586A (en) | 2023-02-16 |
| JP7441473B2 (en) | 2024-03-01 |
| MX2020002086A (en) | 2020-10-28 |
| BR112020003458A2 (en) | 2020-08-25 |
| KR20200044812A (en) | 2020-04-29 |
| CN111107875A (en) | 2020-05-05 |
| PH12020500400A1 (en) | 2021-01-04 |
| WO2019045075A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201709456D0 (en) | Therapeutic agents | |
| IL272864A (en) | Il-33 antagonist-containing therapeutic agent for endometriosis | |
| GB201707153D0 (en) | Therapy | |
| GB201708663D0 (en) | Therapy | |
| GB201719646D0 (en) | Therapy | |
| GB202211038D0 (en) | Payment handoff system | |
| GB201714777D0 (en) | Agent | |
| GB201700553D0 (en) | Therapeutic agents | |
| GB2568266B (en) | Therapeutic device | |
| IL268046A (en) | Peptides for therapy | |
| ZA202103582B (en) | Dna-cutting agent | |
| ZA202103578B (en) | Dna-cutting agent | |
| ZA202001418B (en) | Therapeutic indazoles | |
| GB201702921D0 (en) | Therapeutic agent | |
| GB201702047D0 (en) | Therapeutic agents | |
| GB201702052D0 (en) | Therapeutic agents | |
| GB201701631D0 (en) | Therapeutic agents | |
| GB201701570D0 (en) | Therapeutic agents | |
| GB201700567D0 (en) | Therapeutic agents | |
| GB201715430D0 (en) | Therapy | |
| GB201704311D0 (en) | Therapeutic binding agents | |
| GB201707945D0 (en) | Cnacer therapy | |
| GB201707183D0 (en) | Macrophage-based therapy | |
| GB201703453D0 (en) | Therapy | |
| GB201703070D0 (en) | Therapy |